SCHEMBL3105485

SCHEMBL3105485

CC(C)[Si](Oc1ccc(CO)cc1)(C(C)C)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.44
PPARG P37231 2/20 0.41
PPARA Q07869 2/20 0.41
NR1H4 Q96RI1 2/20 0.35
CYSLTR1 Q9Y271 1/20 0.35
KDR P35968 1/20 0.35
TEK Q02763 1/20 0.35
NPBWR1 P48145 1/20 0.35
MCHR1 Q99705 1/20 0.35
TSHR P16473 1/20 0.34
POLB P06746 1/20 0.34
SLC6A4 P31645 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6179468 0.85 CYP4F2 (0.45) LTA4HPPARATSHRHRH3
SCHEMBL4515768 0.82 PPARA (0.46) LTA4HPPARA
SCHEMBL3085551 0.82 TRPA1 (0.36) TSHRPOLBSLC6A4
SCHEMBL1618477 0.80 CYP4F2 (0.36)
SCHEMBL22398087 0.80 SLC6A4 (0.33) POLBSLC6A4
SCHEMBL18824993 0.80 PARP1 (0.41) LTA4HPPARGPPARANR1H4CYSLTR1
SCHEMBL8213514 0.80 CYP4F2 (0.36)
SCHEMBL2101723 0.78 POLB (0.62) POLB
SCHEMBL2327318 0.78 TAAR1 (0.45) NR1H4CYSLTR1KDRTSHRPRSS1
SCHEMBL15033738 0.78 POLB (0.46) NR1H4TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466784-B2 Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis APICAL MOLECULAR BIOTECH CO., LTD. (TW) 2025-11-11 US disclosed
EP-4136063-B1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS APICAL MOLECULAR BIOTECH CO LTD (TW) 2025-10-22 EP disclosed
US-12370158-B2 Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation OMEICOS THERAPEUTICS GMBH (DE) 2025-07-29 US disclosed
US-12286426-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2025-04-29 US disclosed
CN-119367342-A CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation 奥迈科斯治疗公司 2025-01-28 CN disclosed
EP-3704111-B1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2024-10-09 EP disclosed
EP-3435993-B1 ANALOG OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION OMEICOS THERAPEUTICS GMBH (DE) 2024-09-25 EP disclosed
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed
US-20230234912-A1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS APICAL MOLECULAR BIOTECH CO., LTD. (TW) 2023-07-27 US disclosed
US-8796253-B2 Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-05 US disclosed
US-8796253-B2 Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-05 US disclosed
US-20100249085-A1 HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-30 US disclosed
US-20100249085-A1 HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-30 US disclosed
EP-2148877-A2 INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS Bayer Schering Pharma AG (DE) 2010-02-03 EP disclosed
WO-2008141731-A2 INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE AG (DE) 2008-11-27 WO disclosed
US-20080221303-A1 Method for the Preparation of Peptide-Oligonucleotide Conjugates FRUTAROM LTD. (IL) 2008-09-11 US disclosed
US-20080221303-A1 Method for the Preparation of Peptide-Oligonucleotide Conjugates FRUTAROM LTD. (IL) 2008-09-11 US disclosed
EP-1725250-A2 METHOD FOR THE PREPARATION OF PEPTIDE-OLIGONUCLEOTIDE CONJUGATES FRUTAROM LTD. (IL) 2006-11-29 EP disclosed
WO-2005076744-A2 METHOD FOR THE PREPARATION OF PEPTIDE-OLIGONUCLEOTIDE CONJUGATES FRUTAROM LTD. (IL) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 LTA4H 4822/4885PPARG 1382/4885PPARA 1918/4885
US-20230234912-A1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS FABP1, GLS2, SLC1A5 LTA4H 2847/4885PPARG 123/4885PPARA 59/4885
US-12466784-B2 Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis FABP1, GLS2, SLC1A5 LTA4H 2969/4885PPARG 116/4885PPARA 58/4885
US-20080221303-A1 Method for the Preparation of Peptide-Oligonucleotide Conjugates VIP, PTMS, SSTR4 LTA4H 2755/4885PPARG 4273/4885PPARA 2979/4885
US-20100249085-A1 HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS FLT4, VEGFA, MKI67 LTA4H 2819/4885PPARG 54/4885PPARA 155/4885
US-12286426-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, IDH1 LTA4H 4822/4885PPARG 1382/4885PPARA 1918/4885
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, NUTF2 LTA4H 4825/4885PPARG 1156/4885PPARA 1808/4885
US-12370158-B2 Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation ALOX5, ALOX15B, ALOX15 LTA4H 70/4885PPARG 204/4885PPARA 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.